Clinical Trials · NCT03043664
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
- Phase
- Phase 1/Phase 2
- Recruitment status
- Completed
- Sponsor
- Duke University
- Enrollment
- 22
- Start date
- Jul 2017
- Locations
- 2 sites, United States
- Primary endpoint
- Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)